Rose Travers
Overview
Explore the profile of Rose Travers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Homan E, Rauch F, Grafe I, Lietman C, Doll J, Dawson B, et al.
J Bone Miner Res
. 2011 Aug;
26(12):2798-803.
PMID: 21826736
Osteogenesis imperfecta (OI) is a spectrum of genetic disorders characterized by bone fragility. It is caused by dominant mutations affecting the synthesis and/or structure of type I procollagen or by...
2.
Land C, Rauch F, Travers R, Glorieux F
Bone
. 2006 Nov;
40(3):638-44.
PMID: 17127117
Cyclical intravenous treatment with pamidronate is of clinical benefit in children with moderate to severe osteogenesis imperfecta (OI) types I, III and IV, but there is no information on the...
3.
Rauch F, Travers R, Glorieux F
Bone
. 2006 Oct;
40(2):274-80.
PMID: 17049943
Although intracortical bone remodeling is a key aspect of bone physiology, very little is known about this process during human bone development. In this study, we examined transiliac bone samples...
4.
Rauch F, Travers R, Glorieux F
J Bone Miner Res
. 2006 Apr;
21(4):513-9.
PMID: 16598370
Unlabelled: Transiliac cortical bone histomorphometry was performed in 56 metabolic bone disease-free individuals 1.5-22.9 years of age. During the growing years, the two cortices of an iliac bone specimen differ...
5.
Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy
Rauch F, Travers R, Glorieux F
J Clin Endocrinol Metab
. 2005 Nov;
91(2):511-6.
PMID: 16291701
Context: Intravenous pamidronate treatment is beneficial to children and adolescents with osteogenesis imperfecta (OI), but the effects of prolonged therapy are not well characterized. Objective: The objective of this study...
6.
Zeitlin L, Rauch F, Travers R, Munns C, Glorieux F
Bone
. 2005 Sep;
38(1):13-20.
PMID: 16162424
Intravenous treatment with pamidronate is beneficial in children and adolescents with moderate to severe forms of osteogenesis imperfecta (OI) types I, III and IV, but there is little information on...
7.
Munns C, Rauch F, Travers R, Glorieux F
J Bone Miner Res
. 2005 Jun;
20(7):1235-43.
PMID: 15940378
Unlabelled: Clinical and histomorphometric outcome was compared between children with OI who had received pamidronate since infancy and age-matched patients who had never received pamidronate. Pamidronate was associated with improved...
8.
Munns C, Rauch F, Travers R, Glorieux F
Bone
. 2004 Nov;
35(5):1023-8.
PMID: 15542026
In this report, we describe three unrelated children with an apparently novel bone fragility disorder that is associated with an idiopathic mineralization defect. Recurrent lower limb fractures started with weight...
9.
Rauch F, Travers R, Munns C, Glorieux F
J Bone Miner Res
. 2004 Jun;
19(7):1191-3.
PMID: 15177003
No abstract available.
10.
Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux F
J Clin Endocrinol Metab
. 2003 Oct;
88(10):4569-75.
PMID: 14557424
Intravenous infusions with the bisphosphonate compound pamidronate decrease bone pain and reportedly can lead to refilling of dysplastic lesions in adults with fibrous dysplasia (FD) of bone. Here we describe...